These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33431996)

  • 1. Mid-regional pro-adrenomedullin is a novel biomarker for arterial stiffness as the criterion for vascular failure in a cross-sectional study.
    Koyama T; Kuriyama N; Suzuki Y; Saito S; Tanaka R; Iwao M; Tanaka M; Maki T; Itoh H; Ihara M; Shindo T; Uehara R
    Sci Rep; 2021 Jan; 11(1):305. PubMed ID: 33431996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of mid-regional pro-adrenomedullin levels to cardiovascular and metabolic abnormalities, and mortality in an elderly population from the community.
    Eggers KM; Venge P; Lindahl B; Lind L
    Int J Cardiol; 2013 Oct; 168(4):3537-42. PubMed ID: 23722054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mid-regional pro-adrenomedullin in patients with acute dyspnea: Data from the Akershus Cardiac Examination (ACE) 2 Study.
    Pervez MO; Lyngbakken MN; Myhre PL; Brynildsen J; Langsjøen EC; Høiseth AD; Christensen G; Omland T; Røsjø H
    Clin Biochem; 2017 May; 50(7-8):394-400. PubMed ID: 28065681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of hemodynamic stress and aortic stiffness after STEMI: a cross-sectional analysis.
    Reinstadler SJ; Feistritzer HJ; Klug G; Mayr A; Huybrechts L; Hammerer-Lercher A; Mair J; Franz WM; Metzler B
    Dis Markers; 2015; 2015():717032. PubMed ID: 25960598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple endothelial biomarkers and noninvasive vascular function in the general population: the Gutenberg Health Study.
    Schnabel RB; Wild PS; Schulz A; Zeller T; Sinning CR; Wilde S; Kunde J; Lubos E; Lackner KJ; Warnholtz A; Gori T; Blankenberg S; Munzel T;
    Hypertension; 2012 Aug; 60(2):288-95. PubMed ID: 22689741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mid-regional pro-adrenomedullin in the early evaluation of acute chest pain patients.
    Haaf P; Twerenbold R; Reichlin T; Faoro J; Reiter M; Meune C; Steuer S; Bassetti S; Ziller R; Balmelli C; Campodarve I; Zellweger C; Kilchenmann A; Irfan A; Papassotiriou J; Drexler B; Mueller C
    Int J Cardiol; 2013 Sep; 168(2):1048-55. PubMed ID: 23199555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and prognostic value of procalcitonin and mid-regional pro-adrenomedullin in septic paediatric patients.
    Solé-Ribalta A; Bobillo-Pérez S; Valls A; Girona-Alarcón M; Launes C; Cambra FJ; Jordan I; Esteban E
    Eur J Pediatr; 2020 Jul; 179(7):1089-1096. PubMed ID: 31974673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease.
    Neumann JT; Tzikas S; Funke-Kaiser A; Wilde S; Appelbaum S; Keller T; Ojeda-Echevarria F; Zeller T; Zwiener I; Sinning CR; Jagodzinski A; Schnabel RB; Lackner KJ; Münzel T; Blankenberg S; Wild PS; Sydow K
    Atherosclerosis; 2013 Jun; 228(2):451-9. PubMed ID: 23562132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mid-regional pro-adrenomedullin is associated with pulse pressure, left ventricular mass, and albuminuria in African Americans with hypertension.
    Al-Omari MA; Khaleghi M; Mosley TH; Turner ST; Morgenthaler NG; Struck J; Bergmann A; Kullo IJ
    Am J Hypertens; 2009 Aug; 22(8):860-6. PubMed ID: 19424162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can mid-regional pro-adrenomedullin (MR-proADM) increase the prognostic accuracy of NEWS in predicting deterioration in patients admitted to hospital with mild to moderately severe illness? A prospective single-centre observational study.
    Graziadio S; O'Leary RA; Stocken DD; Power M; Allen AJ; Simpson AJ; Price DA
    BMJ Open; 2019 Feb; 8(11):e020337. PubMed ID: 30798282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of circulating MR-proADM with all-cause and cardiovascular mortality in the general population: Results from the KORA F4 cohort study.
    Gar C; Thorand B; Herder C; Sujana C; Heier M; Meisinger C; Peters A; Koenig W; Rathmann W; Roden M; Stumvoll M; Maalmi H; Meitinger T; Then H; Seissler J; Then C
    PLoS One; 2022; 17(1):e0262330. PubMed ID: 34990470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation between Mid-Regional Pro-Adrenomedullin in Patients with Chronic Heart Failure and the Dose of Diuretics in 2-Year Follow-Up-Data from FAR NHL Registry.
    Špinarová M; Špinar J; Špinarová L; Krejčí J; Goldbergová-Pávková M; Pařenica J; Ludka O; Málek F; Ošťádal P; Benešová K; Jarkovský J; Lábr K
    Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of midregional pro-adrenomedullin as a marker of organ damage and predictor of mortality in patients with sepsis.
    Bernal-Morell E; García-Villalba E; Vera MDC; Medina B; Martinez M; Callejo V; Valero S; Cinesi C; Piñera P; Alcaraz A; Marin I; Muñoz A; Cano A
    J Infect; 2018 Mar; 76(3):249-257. PubMed ID: 29246637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations of cardiac stress biomarkers with incident type 2 diabetes and changes in glucose metabolism: KORA F4/FF4 study.
    Sujana C; Seissler J; Jordan J; Rathmann W; Koenig W; Roden M; Mansmann U; Herder C; Peters A; Thorand B; Then C
    Cardiovasc Diabetol; 2020 Oct; 19(1):178. PubMed ID: 33066780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial.
    Travaglino F; Russo V; De Berardinis B; Numeroso F; Catania P; Cervellin G; Nigra SG; Geraci F; Bressan MA; Guerrini S; Cavazza M; Folli C; Monzani V; Battista S; Mengozzi G; Noto P; Carpinteri G; Semplicini A; Stella F; Ingrassia S; Moscatelli P; Giuntini P; Salerno G; Cardelli P; Di Somma S
    Am J Emerg Med; 2014 Apr; 32(4):334-41. PubMed ID: 24559907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mid-regional pro-adrenomedullin predicts poor outcome in non-selected patients admitted to an intensive care unit.
    Bellia C; Agnello L; Lo Sasso B; Bivona G; Raineri MS; Giarratano A; Ciaccio M
    Clin Chem Lab Med; 2019 Mar; 57(4):549-555. PubMed ID: 30157027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of age on the prognostic value of mid-regional pro-adrenomedullin in the general population.
    Brouwers FP; de Boer RA; van der Harst P; Struck J; de Jong PE; de Zeeuw D; Gans RO; Gansevoort RT; Hillege HL; van Gilst WH; Bakker SJ
    Heart; 2012 Sep; 98(18):1348-53. PubMed ID: 22821276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and prognostic role of procalcitonin (PCT) and MR-pro-Adrenomedullin (MR-proADM) in bacterial infections.
    Angeletti S; Spoto S; Fogolari M; Cortigiani M; Fioravanti M; De Florio L; Curcio B; Cavalieri D; Costantino S; Dicuonzo G
    APMIS; 2015 Sep; 123(9):740-8. PubMed ID: 26058482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mid regional pro-adrenomedullin for the prediction of organ failure in infection. Results from a single centre study.
    Viaggi B; Poole D; Tujjar O; Marchiani S; Ognibene A; Finazzi S
    PLoS One; 2018; 13(8):e0201491. PubMed ID: 30102716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of plasma MR-proADM vs NT-proBNP for heart failure in people with type 2 diabetes: the SURDIAGENE prospective study.
    Fraty M; Velho G; Gand E; Fumeron F; Ragot S; Sosner P; Mohammedi K; Gellen B; Saulnier PJ; Halimi JM; Montaigne D; Ducrocq G; Rehman M; Marre M; Roussel R; Hadjadj S;
    Diabetologia; 2018 Dec; 61(12):2643-2653. PubMed ID: 30232509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.